Small-Molecule GCase Activators Beyond Costly Enzyme Replacement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Gaucher's disease and Parkinson's disease, particularly neuronopathic forms of Gaucher's disease, are expensive and ineffective, and there is limited success in discovering small molecule compounds to activate glucocerebrosidase (GCase) for therapeutic benefit.
Innovation Solution
Development of compounds that modulate GCase activity, including specific chemical structures represented by Formulas (I) and (II), which can be administered to activate GCase and treat associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used to treat Gaucher's disease, then treatment effectiveness is improved, but treatment cost increases significantly
Solution Approach 1:
The patent develops small molecule compounds that can be administered orally at lower costs compared to expensive enzyme replacement therapy. These small molecules act as temporary activators of GCase, providing a more economical treatment option that does not require continuous expensive infusions.
Solution Approach 2:
The patent modifies the approach by changing from replacing the enzyme (ERT) to activating the existing enzyme through small molecule compounds. This parameter change in treatment mechanism enables cost reduction while maintaining therapeutic effectiveness through compounds that enhance GCase activity.
2Adaptability or versatility
If enzyme replacement therapy is used for neuronopathic forms of Gaucher's disease, then treatment coverage is improved, but treatment effectiveness decreases
Solution Approach 1:
The small molecule compounds developed in the patent have broad applicability across different forms of Gaucher's disease, including neuronopathic forms that do not respond well to ERT. These compounds can be administered to patients with various disease manifestations, providing a universal treatment approach that maintains effectiveness across different patient populations.
3Quantity of substance
If small molecule compounds are developed to activate GCase, then treatment cost decreases, but discovery success rate remains limited
Solution Approach 1:
The patent divides the complex task of GCase activation into specific chemical series and structures (Formulas I and II). By segmenting the molecular design into defined components with specific substituents and functional groups, the development process becomes more systematic and reproducible, improving discovery success rates.
Solution Approach 2:
The patent systematically varies chemical parameters such as substituents (R1-R6), functional groups (L, A), and molecular configurations to optimize GCase activation. This parameter optimization approach increases the likelihood of successful compound development by methodically exploring chemical space.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively activate GCase, providing a potential therapeutic option for neurodegenerative diseases like Gaucher's disease and Parkinson's disease, offering a more effective and potentially less costly treatment than existing enzyme replacement therapies.
Implementation Method 1
Glucocerebrosidase (EC 3.2.1.45), also called β-glucocerebrosidase, β-glucosidase, D-glucosyl-N-acylsphingosine glucohydrolase, or GCase, is an enzyme having glucosylceramidase activity. Glucocerebrosidase is required to cleave the beta-glucosidic linkage of the chemical glucocerebroside
Data Source
AI summary
Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease, Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease, Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.